Chromadex Corporation Intrinsic Value Calculation – Chromadex Corporation Reports Q2 FY2023 Earnings Results on June 30, 2023
August 20, 2023
🌥️Earnings Overview
On June 30 2023, CHROMADEX CORPORATION ($NASDAQ:CDXC) announced their second quarter of FY 2023 earnings results. Total revenue was reported at USD 20.3 million, indicating a year-over-year growth of 21.5%. Net income for the quarter was USD -2.2 million, which was an improvement from the -6.4 million reported in the same quarter of the previous year.
Share Price
On Wednesday, June 30, 2023, CHROMADEX CORPORATION reported their fiscal year 2023 second quarter earnings results. The stock opened at $1.6 and closed at $1.6, a 0.6% decrease from the previous closing price of $1.7. Furthermore, the company also paid out $1 million in dividends during the quarter.
Overall, CHROMADEX CORPORATION’s second quarter results demonstrate that the company is on track to achieve its FY2023 goals. Investors are optimistic about the company’s outlook and anticipate further growth in the coming quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Chromadex Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 80.94 | -6.5 | -8.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Chromadex Corporation. More…
| Operations | Investing | Financing |
| 2 | -0.32 | 7.65 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Chromadex Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 53.17 | 26.02 | 0.36 |
Key Ratios Snapshot
Some of the financial key ratios for Chromadex Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 13.9% | – | -10.9% |
| FCF Margin | ROE | ROA |
| 2.1% | -19.9% | -10.3% |
Analysis – Chromadex Corporation Intrinsic Value Calculation
At GoodWhale, we have conducted a thorough analysis of CHROMADEX CORPORATION‘s fundamentals to come to the conclusion that the fair value of their stock is approximately $4.5. This valuation was derived from our proprietary Valuation Line. We have found that CHROMADEX CORPORATION’s stock is currently being traded at $1.6, which marks a 64.5% undervaluation compared to the fair value we derived. This discrepancy between market price and fair value is a great opportunity for investors who are looking for an undervalued stock to add to their portfolio. More…
Peers
In recent years, the market for natural ingredients and supplements has exploded. This has led to intense competition between companies like ChromaDex Corp and its rivals Xeno Transplants Corp, Abcam PLC, and Kidswell Bio Corp. Each company is vying for a piece of the pie, and each has its own unique selling points.
– Xeno Transplants Corp ($OTCPK:XENO)
Xeno Transplants Corp is a company that specializes in transplants using xenotransplantation, which is the transplantation of living cells, tissues, or organs from one species to another. As of 2022, the company has a market cap of 64.58k.
– Abcam PLC ($LSE:ABC)
Abcam PLC is a biotechnology company that develops, manufactures, and sells antibodies and related protein products. The company has a market cap of 3.27B as of 2022 and a return on equity of 2.69%. Abcam’s products are used in scientific research, including drug discovery and development, and in commercial applications such as diagnostics. The company’s products are sold to customers in over 100 countries.
– Kidswell Bio Corp ($TSE:4584)
Kidswell Bio Corp is a pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of rare pediatric diseases. The company has a market cap of 9.18B as of 2022 and a Return on Equity of -10.61%. The company’s products include treatments for rare genetic disorders, cancer, and infectious diseases.
Summary
Investors may find CHROMADEX CORPORATION an attractive opportunity. For the second quarter of FY2023, total revenue increased by 21.5% year over year to USD 20.3 million, while net income improved to -2.2 million from -6.4 million in the same quarter of the previous year. This indicates a positive trend in the company’s financial performance and may be an indication of future earnings potential. With such promising results, investors should consider adding CHROMADEX CORPORATION to their portfolio.
Related Posts
Recent Posts
